**Core tip:** This case report represents the first case of Charcot-Marie-Tooth IA revealed after the administration of docetaxel/trastuzumab/pertuzumab for metastatic breast cancer. This paper will help to focus on the revelation of rare hereditary neuropathies after the administration of chemotherapies.

INTRODUCTION
============

Charcot-Marie-Tooth (CMT) type I neuropathy is the most common hereditary cause of neuropathy. Seventy percent to 80% of these patients present the subtype IA. This disease involves the motor and sensory peripheral nerves. Age of onset is variable; diagnosis is usually made between the age of 5 and 25 years. The diagnosis of CMT IA is confirmed with genetic testing and electro-diagnostic studies. There is no approved medical therapy to prevent the progression of CMT\[[@B1]\].

To our knowledge, we report here the first case of CMT IA revealed in a patient after receiving docetaxel/trastuzumab/pertuzumab for metastatic breast cancer. We first discuss the originality of our case and the potential role of chemotherapies in revealing or accentuating these syndromes. Then, we review the reported cases in the literature describing the relationship between these diseases and different chemotherapeutical agents.

CASE REPROT
===========

We present the case of a 55-year-old patient, with unremarkable past medical history, who was diagnosed with HER2-positive and hormonal receptor positive stage IV metastatic breast cancer in 2014 with a primary tumor of 2.7 cm and one liver metastasis. Her first-line therapy consisted of the standard of care regimen docetaxel combined to trastuzumab and pertuzumab followed by surgery of the primary breast tumor and radiofrequency ablation of the unique metastatic hepatic lesion given an excellent response and the presence of oligometastatic disease.

Chemotherapy was stopped after 6 cycles of docetaxel and the patient was kept on maintenance therapy with trastuzumab and pertuzumab. Three months after the last cycle of chemotherapy, the patient developed numbness in the extremities, generalized depressed tendon reflexes, and hypoesthesia in the lower third of legs. At the clinical examination, pes cavus foot deformity, bilateral foot drop and generalized depressed tendon reflexes were detected.

After a complete anamnesis, the patient mentioned that many members of her family (her sister, her niece and her grand-father) were diagnosed with the CMT type IA disease. A genetic analysis of *PMP22* gene confirmed the diagnosis in our patient and conduction velocity studies demonstrated demyelinating abnormalities concordant with the diagnosis. In fact, multiple ligation-dependent probe amplification of the exons 1-5 of the *PMP22* gene located at 17p11.2 showed genomic duplication comprising the *PMP22* gene.

The patient continued her treatment for breast cancer based on targeted therapies (pertuzumab and trastuzumab) and hormonal therapy (letrozole) and is currently in complete remission. For her stable persistent neurologic deficits physiotherapy was prescribed for maintaining posture and balance, genetic counseling for the family members, namely her two sons, and avoidance of neurotoxic drugs.

DISCUSSION
==========

Neurologic toxicities represent the second most frequent chemotherapy-induced side effect after hematologic toxicities. Vinca-alkaloids, taxanes and platinum-based agents are the most frequent drugs inducing peripheral neurotoxicity. These drugs are used in the treatment of ovarian, breast, lung, prostate, colon and hematological malignancies. Chemotherapy-induced neuropathy is usually dose-dependent. Patients with pre-existing neuropathic symptoms due to diabetes, hereditary neuropathies or earlier treatment with neurotoxic chemotherapy are probably more vulnerable to further development of chemotherapy-induced peripheral neuropathy\[[@B2],[@B3]\].

We report, here, an interesting case of a hereditary CMT IA disease revealed after the administration of docetaxel in combination with anti-HER2 antibodies, in an advanced HER2-positive breast cancer. Our case represents the first case of CMT IA revealed after the administration of docetaxel. It is less likely that this disease was revealed by trastuzumab or pertuzumab, because it was not reported in the literature any CMT related to biologic agents.

A case of an aggravation of CMT after the administration of carboplatin and paclitaxel for ovarian cancer was reported before; the symptomatology resolved after the replacement of paclitaxel by docetaxel, considered as less neurotoxic 4. Thus, our case demonstrates that even less neurotoxic taxanes, as docetaxel, can sometimes reveal or worsen CMT neuropathies.

In some cases, CMT IA has been diagnosed after the administration of neurotoxic drugs including chemotherapeutical agents, mainly vincristine. The cases reported in the literature are summarized in Table [1](#T1){ref-type="table"}.

###### 

Summary of all the reported cases in the literature of Charcot-Marie-Tooth revealed after administration of chemotherapy

  **Ref**.                           **Patient characteristics**   **Drug**                   **Malignancy**                        **Signs and symptoms**                                                                                                                                                            **Diagnosis**
  ---------------------------------- ----------------------------- -------------------------- ------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------
  Uno et al\[[@B7]\], 1999           44 M                          Vincristine                NHL                                   Rapid and marked weakening progressing to quadriplegia and bulbar palsy pes cavus (hollow foot)                                                                                   Slower nerve conduction velocity 17p11.2-12 duplication
  Martino et al\[[@B4]\], 2005       F                             Paclitaxel/ Carboplatine   Ovarian cancer                        Distal sensory and motor neuropathy; Unable to walk, write, or drive                                                                                                              Already diagnosed
  Hildebrandt et al\[[@B8]\], 2000   52 F                          Vincristine                NHL                                   Dysphagia, dysarthria, muscular weakness of both lower and upper extremities, areflexia, paraesthesia of the fingertips and bilateral sensory impairment of feet and lower legs   Peripheral axonal and demyelinating sensorimotor neuropathy 17p11.2 duplication
  Graf et al\[[@B5]\], 1996          9 F                           Vincristine                Acute lymphoblastic leukemia          Severe acquired weakness, areflexia and distal muscle atrophy                                                                                                                     17p duplication
                                     18 F                                                     Burkitt lymphoma                      Pes cavus, distal muscle atrophy and weakness, stocking glove sensory deficits                                                                                                    17p duplication Slower nerve conducting velocity
                                     46 M                                                     Testicular embryonal cell carcinoma   Foot drop, per cavus and areflexia, marked weakness                                                                                                                               Slow motor nerve conduction velocity

NHL: Non-Hodgkin lymphoma; M: Male; F: Female.

A retrospective case series, in three families with known hereditary neuropathies treated with vincristine, concluded that vincristine in patients with 17p11.2-12 may lead to severe neurotoxicity from vincristine and that this drug should not be administered in patients with CMT1A\[[@B5]\]. On the other hand, a recent study of the Mayo Clinic investigated the association of non-CMT polyneuropathy with *CMT* genes in patients treated with paclitaxel. The results demonstrated a relationship between the *CMT* gene allelic variability and the susceptibility to chemotherapy-induced peripheral neuropathy\[[@B6]\].

This case stresses again the importance for oncologists to perform a complete anamnesis on past personal and familial history, before the administration of a neurotoxic chemotherapeutical regimen. It is also crucial to perform a complete neurological examination before administrating neurotoxic chemotherapies to avoid the worsening of non-diagnosed peripheral neuropathies.

COMMENTS
========

Case characteristics
--------------------

The patient presented numbness in the extremities, generalized depressed tendon reflexes, and hypoesthesia in the lower third of legs, 3 mo after the last cycle of chemotherapy.

Clinical findings
-----------------

The clinical examination of the patient revealed pes cavus foot deformity, bilateral foot drop and generalized depressed tendon reflexes.

Differential diagnosis
----------------------

Acute myelitis or Guillain-Barré syndrome are possible differential diagnosis.

Laboratory findings
-------------------

A multiple ligation-dependant probe amplification of the exons 1-5 of the *PMP22* gene located at 17p11.2 showed genomic duplication comprising the *PMP22* gene.

Pathological diagnosis
----------------------

Pathological diagnosis was not necessary.

Treatment
---------

Physiotherapy was prescribed for maintaining posture and balance, genetic counseling for the family members, namely her two sons, and avoidance of neurotoxic drugs.

Experiences and lessons
-----------------------

Perform a complete anamnesis on past personal and familial history, before the administration of a neurotoxic chemotherapeutical regimen. Perform a complete neurological examination before administrating neurotoxic chemotherapies to avoid the worsening of non-diagnosed hereditary peripheral neuropathies.
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